+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cost-Effectiveness of Adding Bedaquiline To Background Drug Regimens For The Treatment of Multidrug-Resistant And Extensively-Resistant Tuberculosis In Italy



Cost-Effectiveness of Adding Bedaquiline To Background Drug Regimens For The Treatment of Multidrug-Resistant And Extensively-Resistant Tuberculosis In Italy



Value in Health 19(7): A553-A554




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 064827486

Download citation: RISBibTeXText

DOI: 10.1016/j.jval.2016.09.1199


Related references

Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK. Plos One 10(3): E0120763, 2016

Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Clinical Infectious Diseases 62(9): 1188-1190, 2017

Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clinical Infectious Diseases 60(2): 188-194, 2015

High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. European Respiratory Journal 2018, 2018

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. European Respiratory Journal 47(2): 564-574, 2016

Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany. Respiratory Medicine 109(5): 632-641, 2016

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. International Journal of Molecular Sciences 18(2), 2017

Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. Journal of Thoracic Disease 9(7): 2093-2101, 2017

Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. Bmc Health Services Research 17(1): 182, 2017

Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis. Expert Review of Pharmacoeconomics and Outcomes Research 18(6): 677-689, 2018

Cost Effectiveness of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis. Value in Health 17(7): A595, 2014

Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. Journal of Thoracic Disease 7(4): 603-615, 2015

Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea. Annals of Laboratory Medicine 38(6): 563-568, 2018

Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China. International Journal of Infectious Diseases 78: 44-49, 2018

Cost-effectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea. Clinical Therapeutics 38(3): 655-67.E1-2, 2016